今日药学

2016, v.26(02) 127-129

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

2型糖尿病2种胰岛素治疗方案的经济学分析
Economic Analysis of 2 kinds of Insulin Treatment for Type 2 Diabetes

陈婉纯;陈东虹;
CHEN Wanchun;CHEN Donghong;The People's Hospital of Jieyang;

摘要(Abstract):

目的探讨临床常用的2种胰岛素治疗方案的临床效果和经济效果。方法将116例2型糖尿病患者根据用药平均分成A、B组,分别给予重组甘精胰岛素注射液+门冬胰岛素30注射液、精蛋白重组人胰岛素混合注射液70/30治疗,并进行经济学分析。结果 A、B组的达标住院总成本分别为528.95元和1 123.62元;达标率分别为94.83%和81.03%;成本-效果比分别为5.58和13.87。结论重组甘精胰岛素注射液+门冬胰岛素30注射液治疗2型糖尿病的成本-效果优于精蛋白重组人胰岛素混合注射液70/30。
OBJECTIVE To investigate the clinical and economic effects of 2 kinds of insulin therapy.METHODS A total of 116 type 2 diabetes patients were divided equally into group A and B based on their different medication,by giving recombinant insulin injection 30+Insulin aspart 30 injection or protamine 70/30 mixed recombinant human insulin injection treatment,respectively.Meanwhile the economic analysis was valued on both groups.RESULTS Total cost of patients reach compliance in the hospital in group A and B was 528.95 yuan and 1 123.62 yuan,respectively.The compliance rate was 94.83% and 81.03%,respectively.Costeffectiveness ratio was 5.58 and 13.87,respectively.CONCLUSION Cost-effectiveness of recombinant Gan insulin glargine injection plus insulin aspart 30 injection treatment for type 2 diabetes is better than that of premixed protamine pecombinant human insulin injection 70/30 treatment.

关键词(KeyWords): 2型糖尿病;重组甘精胰岛素注射液;门冬胰岛素30注射液;精蛋白重组人胰岛素混合注射液70/30;经济学分析
type 2 diabetes;recombinant insulin glargine injection;insulin aspart 30 injection;premixed protamine recombinant human insulin injection 70/30;economic analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈婉纯;陈东虹;
CHEN Wanchun;CHEN Donghong;The People's Hospital of Jieyang;

Email:

DOI:

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享